Payment overview · 2025
General Payments
$213.10
11 reported records · 4 companies
Healthcare provider profile · identity verified
Alex Bernstein, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1366753410
Verified facts
What the public records show
CMS Open Payments records show Alex Bernstein, M.D. received $213.10 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 44.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $95.31 | 44.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.22 | 34.4% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $22.70 | 10.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.87 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $213.10 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $95.31 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $73.22 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $73.22 | 5 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 215 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
215 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
115 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
103 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 797 | 133 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 428 | 70 |
| Metformin Hcl | Metformin Hcl | 388 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 315 | 76 |
| Losartan Potassium | Losartan Potassium | 304 | 61 |
| Omeprazole | Omeprazole | 259 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 40 |
| Eliquis | Apixaban | 235 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 36 |
| Creon | Lipase/Protease/Amylase | 215 | 42 |
| Meclizine Hcl | Meclizine Hcl | 203 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 193 | 65 |
| Carvedilol | Carvedilol | 191 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 39 |
| Meloxicam | Meloxicam | 166 | 101 |
| Linzess | Linaclotide | 160 | 25 |
| Famotidine | Famotidine | 141 | 34 |
| Mounjaro | Tirzepatide | 141 | 27 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 138 | 34 |
| Nebivolol Hcl | Nebivolol Hcl | 134 | 19 |
| Lisinopril | Lisinopril | 128 | 23 |
| Atenolol | Atenolol | 122 | 23 |
| Doxepin Hcl | Doxepin Hcl | 121 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 118 | 22 |
| Azithromycin | Azithromycin | 117 | 78 |
| Ranolazine Er | Ranolazine | 116 | 19 |
| Fenofibrate | Fenofibrate | 115 | 25 |
| Synthroid | Levothyroxine Sodium | 115 | 19 |
| Memantine Hcl | Memantine Hcl | 113 | 25 |
| Gemtesa | Vibegron | 106 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 18 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 100 | 12 |
| Entresto | Sacubitril/Valsartan | 96 | 16 |
| Vascepa | Icosapent Ethyl | 96 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 20 |
| Nifedipine Er | Nifedipine | 91 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 14 |
| Clonidine Hcl | Clonidine Hcl | 88 | 35 |
| Memantine Hcl Er | Memantine Hcl | 81 | 17 |
| Januvia | Sitagliptin Phosphate | 77 | 17 |
| Furosemide | Furosemide | 76 | 18 |
| Azelastine Hcl | Azelastine Hcl | 69 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 22 |
| Ozempic | Semaglutide | 68 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 66 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 61 | 52 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 12 |
| Torsemide | Torsemide | 60 | 13 |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Mirtazapine | Mirtazapine | 54 | 14 |
| Jardiance | Empagliflozin | 53 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 11 |
| Gabapentin | Gabapentin | 49 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 48 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 48 | 18 |
| Amoxicillin | Amoxicillin | 46 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 46 | 16 |
| Prednisone | Prednisone | 46 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 32 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Rybelsus | Semaglutide | 42 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 41 | 12 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 38 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 21 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 36 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Livalo | Pitavastatin Calcium | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | 16 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 27 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Dexilant | Dexlansoprazole | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 11 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 23 | suppressed |
| Ztlido | Lidocaine | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Naproxen | Naproxen | 21 | 17 |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Uloric | Febuxostat | 18 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 17 | 14 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Celecoxib | Celecoxib | 16 | suppressed |
| Exelon | Rivastigmine | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Constulose | Lactulose | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Lunesta | Eszopiclone | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Benicar | Olmesartan Medoxomil | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Jublia | Efinaconazole | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $213.10 · 11 records | GlaxoSmithKline, LLC. | ACCRUFER, CREON, LINZESS, OTEZLA, REPATHA, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error